Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations-Reference-Cited by-同舟云学术

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations

Published:2017-08-25 Issue:11 Volume:25 Page:3295-3304
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Aapro Matti,Boccia Ralph,Leonard Robert,Camps Carlos,Campone Mario,Choquet Sylvain,Danova Marco,Glaspy John,Hus Iwona,Link Hartmut,Sliwa Thamer,Tesch Hans,Valero Vicente

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s00520-017-3842-1/fulltext.html

Reference73 articles.

1. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32. doi: 10.1016/j.ejca.2010.10.013

2. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, Committee EG (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111–v118. doi: 10.1093/annonc/mdw325

3. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad RKV II, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431. doi: 10.1093/cid/ciq147

4. Wang L, Baser O, Kutikova L, Page JH, Barron R (2015) The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. doi: 10.1007/s00520-015-2686-9

5. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916–1924. doi: 10.1002/cncr.20983

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC);2024-01-05

2. The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results;Journal of Modern Oncology;2023-12-10

3. The Effectiveness and Optimal Timing of PEG-rhG-CSF After Autologous Peripheral Blood Stem Cell Transplantation: A Multicenter Experience;Indian Journal of Hematology and Blood Transfusion;2023-10-17

4. Neutropenie – wann ist eine GCSF Unterstützung notwendig?;Aktuelle Urologie;2023-08-22

5. Clinical decision support for chemotherapy‐induced neutropenia using a hybrid pharmacodynamic/machine learning model;CPT: Pharmacometrics & Systems Pharmacology;2023-08-10